
    
      This is an Italian multi-center randomized phase II trial (randomization 2:1) of intravenous
      (IV) MK-3475 (Pembrolizumab) versus observation as a maintenance therapy after
      chemo-radiotherapy (either concomitant or sequential, regardless of the type of chemotherapy
      used) in unresectable stage IIIA-IIIB non small cell lung cancer (NSCLC) patients.
    
  